CBD and THC May Inhibit Glioblastoma Progression: New Polish Study Identifies Mechanism

A new study published this month in the Journal of Applied Genetics reports that CBD, THC and a whole-cannabis extract inhibit the progression of glioblastoma — both alone and when combined with temozolomide, the current standard chemotherapy for the disease. The work, led by researchers at Poznan University of Medical Sciences and the Institute of Bioorganic Chemistry of the Polish Academy of Sciences, advances a question that cannabis cancer researchers have been chasing for nearly two decades: not just whether cannabinoids slow glioma cells in a dish, but how they do it at the level of DNA. The team identifies a previously underexplored mechanism — cannabinoid-induced DNA hypermethylation — and offers a structural explanation for why THC specifically might intercalate into the double helix.

Glioblastoma is the most aggressive primary brain cancer in adults, with a median survival of roughly 15 months after diagnosis and a five-year survival rate that remains under 7% despite four decades of investment. Standard care — maximum safe surgical resection followed by radiotherapy and temozolomide — leaves most patients facing recurrence within a year. The Polish study does not change clinical practice this morning. But it adds a sharper molecular target for a class of compounds patients and physicians have asked about for years.

What the Researchers Did

The team tested three preparations in glioblastoma cell models: pure cannabidiol (CBD), pure tetrahydrocannabinol (THC), and a defined cannabis extract the authors refer to as CFE. Each was assessed alone and in combination with temozolomide (TMZ). Endpoints included cell-progression markers, viability assays, and — distinctively — methylation status of genes implicated in glioblastoma proliferation and chemoresistance.

The findings unfolded in three layers.

First, each preparation slowed glioblastoma progression on its own, with the cannabis extract (a combination of cannabinoids and minor compounds) generally outperforming the isolated single-molecule preparations at equivalent total cannabinoid concentrations. The differential is consistent with the entourage-effect hypothesis that cannabinoid researchers have argued for since the late 1990s.

Second, combinations of CBD or THC with temozolomide produced greater inhibition than TMZ alone. The combined effect was additive at lower doses and trended toward synergy at higher concentrations — a result that, if it holds up in animal models, could meaningfully reduce the temozolomide dose required to achieve a given progression-free interval, lowering toxicity without sacrificing efficacy.

Third, and most novel: CBD and THC both induced hypermethylation at gene loci linked to glioblastoma cell proliferation. The authors propose a mechanism in which cannabinoids interact directly with DNA and DNA methyltransferase (DNMT), the enzyme family responsible for adding methyl groups to cytosine residues. They argue THC's planar molecular structure is geometrically capable of intercalating between DNA base pairs, a positioning that could modulate methyltransferase access. CBD, while less planar, may influence methylation through DNMT binding rather than direct intercalation.

Why the Mechanism Matters

The cannabinoid–glioblastoma literature is not new. Spanish researchers led by Manuel Guzmán have published on cannabinoid effects against glioma since the early 2000s, and Phase 1 and 2 trials of THC and CBD in combination with temozolomide have run in the UK and Europe. A 2017 GW Pharmaceuticals study in 21 patients reported that adding a THC:CBD combination to TMZ improved one-year survival from 53% to 83%, though small sample sizes have prevented the result from changing clinical practice.

What earlier work mostly demonstrated was activity — cannabinoids kill glioblastoma cells through some combination of apoptosis induction, autophagy activation, and antiangiogenic effects. What earlier work mostly did not demonstrate is a specific, druggable mechanism that links cannabinoid receptor signaling to the epigenetic state of the cancer genome. The Polish study contributes that missing piece by tying cannabinoid exposure to DNA methylation patterns.

The clinical relevance is twofold. Methylation-based mechanisms are druggable in ways that vague "cell-stress" mechanisms are not — there are FDA-approved DNMT inhibitors (azacitidine, decitabine) used in myelodysplastic syndromes, and any compound that modulates DNMT function in the brain has at least a theoretical synergy partner already on the shelf. Second, the temozolomide story itself is partly an epigenetics story: the MGMT promoter methylation status of a glioblastoma is the single best predictor of whether TMZ will work. A cannabinoid that pushes the methylation landscape in a direction that potentiates TMZ would, in principle, expand the patient pool who benefits from existing chemotherapy.

What This Doesn't Mean

The study is preclinical — a laboratory result in cell models, not a clinical trial in patients. The history of glioblastoma research is studded with promising in vitro signals that did not survive Phase 3 trials. Three caveats are worth holding in mind.

First, the doses required to produce cannabinoid effects in laboratory glioblastoma models are higher than what is reliably achievable in the bloodstream and brain of a patient taking oral CBD or smoking cannabis flower. Bioavailability and blood-brain-barrier penetration are unsolved problems for cannabinoid oncology.

Second, the patients most likely to ask about cannabis-based treatment are already on temozolomide, often with radiotherapy, and frequently on corticosteroids and antiepileptic drugs. Drug–drug interactions are non-trivial — CBD in particular inhibits cytochrome P450 enzymes that metabolize many of the medications glioblastoma patients are simultaneously taking. The Polish study did not address these clinical pharmacology questions.

Third, hypermethylation can suppress tumor-suppressor genes as well as proto-oncogenes, depending on which loci are affected. The therapeutic window between "good methylation" and "bad methylation" is narrow and patient-specific.

What Comes Next

The Polish team explicitly frames its results as motivating further preclinical work — animal models with cannabinoid–TMZ combination dosing, followed by formal Phase 1/2 trials with pharmacokinetic monitoring. Clinical trials at UC San Diego and the University of California Health system are already running cannabinoid protocols in adjacent oncology indications, and the Spanish glioma research consortium has indicated interest in revisiting THC:CBD combinations in light of newer immunotherapy backbones for glioblastoma.

For patients with glioblastoma today, the responsible read is that the Polish study supports continued research, not self-medication. Anyone considering adding cannabis to a glioblastoma treatment regimen should do so only in consultation with their oncologist — both because of the drug–drug interaction landscape and because clinical-trial enrollment criteria typically exclude patients who started cannabinoids outside the protocol.

Where Cannabinoid Oncology Stands in May 2026

This is now the second high-profile cannabinoid–cancer paper of the spring. Earlier in May, separate research reported that THC and CBD enhanced the anti-cancer effects of cisplatin in cervical cancer cells, and a parallel breast cancer study found CBD triggered apoptotic activity in both standard and drug-resistant lines. The cumulative effect is to put cannabinoids back on the oncology research map after a decade in which the field was crowded out by immunotherapy and targeted small-molecule inhibitors.

What's different about the 2026 cycle is that the regulatory environment is finally catching up to the science. The DEA's April 23 rescheduling order moved FDA-approved and state-licensed medical cannabis products to Schedule III, sharply lowering the procedural cost of running cannabinoid clinical trials. Universities that previously declined to host cannabinoid oncology programs because of Schedule I research barriers are now in a position to launch them.

Key Takeaways

• A May 2026 Polish study in the Journal of Applied Genetics found that CBD, THC and a cannabis extract inhibit glioblastoma progression in cell models, both alone and with temozolomide.
• The proposed mechanism involves cannabinoid-induced DNA hypermethylation, with THC's planar structure potentially allowing intercalation into the DNA double helix.
• The combination of cannabinoids with temozolomide produced additive and trending-toward-synergistic effects, suggesting potential to reduce TMZ doses while preserving efficacy.
• Results are preclinical and do not yet support clinical use of cannabis outside formal trials, particularly because of bioavailability gaps and drug–drug interactions.
• The study is the latest in a cluster of 2026 cannabinoid oncology papers and arrives just as the DEA's Schedule III rescheduling reduces research barriers in the United States.

Explore cannabis news, find dispensaries, and join the community at Budpedia.